Truist Financial Cuts OrthoPediatrics (NASDAQ:KIDS) Price Target to $28.00

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) had its price objective reduced by research analysts at Truist Financial from $34.00 to $28.00 in a note issued to investors on Monday, Benzinga reports. The brokerage currently has a "hold" rating on the stock. Truist Financial's target price would indicate a potential upside of 7.90% from the stock's current price.

KIDS has been the topic of several other reports. Needham & Company LLC restated a "buy" rating and issued a $42.00 target price on shares of OrthoPediatrics in a research note on Friday, September 13th. JMP Securities reissued a "market outperform" rating and issued a $50.00 price objective on shares of OrthoPediatrics in a report on Friday, September 13th.

OrthoPediatrics Stock Performance

KIDS traded up $1.34 during trading on Monday, hitting $25.95. 230,643 shares of the company traded hands, compared to its average volume of 168,337. OrthoPediatrics has a one year low of $23.10 and a one year high of $36.23. The stock's fifty day moving average is $28.51 and its 200 day moving average is $30.13. The company has a quick ratio of 1.96, a current ratio of 4.90 and a debt-to-equity ratio of 0.03. The firm has a market cap of $618.36 million, a P/E ratio of -27.03 and a beta of 1.17.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last released its earnings results on Monday, August 5th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.08. The firm had revenue of $52.80 million during the quarter, compared to the consensus estimate of $52.40 million. OrthoPediatrics had a negative net margin of 14.35% and a negative return on equity of 5.44%. As a group, equities analysts predict that OrthoPediatrics will post -0.92 EPS for the current fiscal year.

Insider Activity at OrthoPediatrics

In other OrthoPediatrics news, General Counsel Daniel J. Gerritzen sold 10,000 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $29.30, for a total transaction of $293,000.00. Following the sale, the general counsel now owns 77,304 shares in the company, valued at $2,265,007.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 31.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On OrthoPediatrics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of OrthoPediatrics by 1.3% in the first quarter. Vanguard Group Inc. now owns 883,827 shares of the company's stock worth $25,772,000 after buying an additional 11,100 shares in the last quarter. Wasatch Advisors LP raised its holdings in shares of OrthoPediatrics by 21.2% in the 1st quarter. Wasatch Advisors LP now owns 501,310 shares of the company's stock valued at $14,618,000 after acquiring an additional 87,657 shares in the last quarter. AWM Investment Company Inc. boosted its position in shares of OrthoPediatrics by 14.6% during the 1st quarter. AWM Investment Company Inc. now owns 487,619 shares of the company's stock valued at $14,219,000 after acquiring an additional 62,000 shares during the last quarter. Wellington Management Group LLP purchased a new position in shares of OrthoPediatrics during the fourth quarter worth about $10,214,000. Finally, Paradigm Capital Management Inc. NY increased its position in shares of OrthoPediatrics by 8.0% in the second quarter. Paradigm Capital Management Inc. NY now owns 134,400 shares of the company's stock worth $3,865,000 after purchasing an additional 10,000 shares during the last quarter. 69.05% of the stock is owned by hedge funds and other institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.